Effect of Olvanil Supplementation on Clinical, Biochemical and Anthropometric Parameters in Obese Adults

Not Applicable

Recruiting

• Conditions: Obesity
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: Olvanil

• Registration Number: NCT05857306
• Lead Sponsor: University of Guadalajara

Brief Summary

Capsaicinoids are defined as alkaloid compounds of the Capsicum genus, they are characterised by the pungent flavor of chili. About the Capsicum genus, there are more than 20 known compounds, including dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin and homocapsaicin. Capsaicin is the most popular compound in the biotechnological food industries. Recent studies has demonstrated the benefits of capsaicin in weight loss, however, the use of this molecule is limited given its high pungent capacity. Pungency develops due to the high affinity of capsaicin for the transient vanilloid potential receptor type 1 (TRPV1), which is primarily responsible for the transmission of pain. In order to eliminate pungency, capsaicin analogs have been developed, such as olvanil, this can become an alternative for its biotechnological and pharmaceutical purposes as an antiobesogenic treatment.

Detailed Description

A total of 56 subjects will be invited to be enrolled in a study approaching the properties of a capsaicin analog: olvanil, along with nutritional guidance.

This double blind, randomized, parallel clinical trial will consist in a 8-week intervention with recurrent visits every 4 weeks. In every visit, all subjects will undergo a body composition analysis as well as blood tests.

This study proposes three objectives for reaching a further understanding of the effects of olvanil:

1. Compare the anthropometric parameters at baseline versus final time between the groups.

2. Compare the clinical parameters at baseline versus final time between groups.

3. Compare the concentrations of the biochemical parameters at baseline versus final time between the groups.

Once the project is finished, the research strategies for new studies will be improved. In the same way, the application of the knowledge generated in it will be encouraged towards the health care of patients with obesity who could attend our service on future occasions. Finally, we would disseminate the knowledge generated in our institutional community, which would increase the impact of the project.

Study Timeline

• Study Start: 2023-02-20
• Study First Submitted: 2023-02-20
• Status Verified: 2023-05
• Study First Submitted QC: 2023-05-10
• Last Update Submitted: 2023-05-10
• Study First Posted: 2023-05-12
• Last Update Posted: 2023-05-12
• Primary Completion: 2023-07-31
• Study Completion: 2023-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

• 25-59 years of age
• Both sexes
• Subjects who agree to participate in the study and all signed informed consent
• BMI 30 kg/m2 - 39.9 kg/m2

Exclusion Criteria

• Currently consuming any of the following drugs: NSAIDs, anticoagulants, hypoglycemic, oR hypolipemic drugs
• Diagnosed autoimmune diseases
• Diagnosed cancer
• Pregnancy and breastfeeding
• Suffering from gastritis and hemorrhoids
• Subjects who wish to abandon the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Olvanil	Olvanil	-

Primary Outcome Measures

Name	Time	Method
Analysis of anthropometric variable (BMI)	8 weeks	BMI will be calculate as weight in kilograms divided by height in square meters (kg/m2).
Analysis of clinic variables (Systolic and diastolic blood pressure)	8 weeks	The measurement of systolic and diastolic blood pressure will be carry out with a OMRON wireless upper arm blood pressure monitor, and represented millimeters of mercury (mmHg)
Analysis of biochemicals variables (Glucose)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; - Glucose (Glu) mg/dL; Will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Triglycerides)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Triglycerides (TG) mg/dL,; Will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Total cholesterol)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Total cholesterol (TC) mg/dL,; Will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (High-density lipoprotein)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - High-density lipoprotein (HDL) mg/dL,; Will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Low-density lipoprotein)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Low-density lipoprotein (LDL) mg/dL,; Will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Very low-density lipoprotein)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Very low-density lipoprotein (VLDL) mg/dL,; will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Creatinine)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Creatinine (mg/dL),; will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of anthropometric variable (Height)	8 weeks	The measure will be performe without shoes, and an Height measurement will be determine by a stadiometer and represented in meters.
Analysis of anthropometric variable (Waist circumference)	8 weeks	The measure will be performe with light clothes. Waist circumference (WC) represented in centimeters was measured using a Lufkin Executive® Thinline 2-mm measuring tape.
Analysis of anthropometric variable (Body fat percentage)	8 weeks	The measure will be performe without shoes, with light clothes. Tetrapolar body electrical bioimpedance will be use to assess body fat percentage using InBody 370 and RJL Quantum V.
Analysis of anthropometric variable (Weight)	8 weeks	The measure will be performe without shoes, with light clothes and represented in kilograms Tetrapolar body electrical bioimpedance will be use to assess weight using InBody 370.
Analysis of biochemicals variables (Serum bilirubin)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Serum bilirubin (mg/dL),; will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Aspartate amino transaminase)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Aspartate amino transaminase (U/L),; will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Alanine amino transaminase)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Alanine amino transaminase (U/L); will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Gamma glutamyl transpeptidase)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Gamma glutamyl transpeptidase (U/L),; will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Alkaline phosphatase)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Alkaline phosphatase (U/L); will be carry out by dry chemistry using a Vitros 350 Analyzer.
Analysis of biochemicals variables (Urea)	8 weeks	Biochemical measurements at baseline and after 8 weeks supplementation Blood samples will be taken after 8 to 10 h of fasting and then centrifuged to obtain the serum, which will be frozen at -80 °C.; Determinations of: - Urea (mg/dL); will be carry out by dry chemistry using a Vitros 350 Analyzer.

Trial Locations

Locations (2)

University of Guadalajara; 🇲🇽 Guadalajara, Jaliscco, Mexico

Universidad de Guadalajara; 🇲🇽 Guadalajara, Jalisco, Mexico